In a trial, Pfizer-BioNTech’s low-dose shot did not provoke an adequate immune response in 2- to 5-year-olds.

By BY APOORVA MANDAVILLI AND REBECCA ROBBINS from NYT World https://ift.tt/3sf8pnX